日报更新时间：
周报更新时间：01-16 11:49
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：Tenax疗法
英文名称：Tenax Therapeutics
简介：Tenax Therapeutics, Inc.最初是在一家新泽西公司名下的公司，于1967年成立的，那家新泽西公司叫Rudmer, David & Associates, 随后更名为Synthetic Blood International公司
电话：1-919-8552100
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-07-30 | Jebsen (Michael B) | Chief Financial Officer | Sell | 54 | 0.65 |
| 2017-04-14 | Jebsen (Michael B) | Chief Financial Officer | Sell | 56 | 0.54 |
| 2017-03-14 | Kelley (John P) | Chief Executive Officer | Sell | 96999 | 0.68 |
| 2017-03-14 | Kelley (John P) | Chief Executive Officer | Buy | 213420 | -- |
| 2016-12-18 | Jebsen (Michael B) | Chief Financial Officer | Sell | 49 | 2.07 |
| 2016-11-22 | Proehl (Gerald T) | Director | Buy | 14449 | 1.76 |
| 2016-11-21 | Proehl (Gerald T) | Director | Buy | 15433 | 1.59 |
| 2016-11-20 | Mitchum James P | Director | Buy | 7000 | 1.51 |
| 2016-09-29 | Jebsen (Michael B) | Chief Financial Officer | Sell | 49 | 2.32 |
| 2016-08-18 | Rallis (Christopher A) | Director | Buy | 10000 | 2.50 |
| 2016-05-31 | Jebsen (Michael B) | Chief Financial Officer | Sell | 55 | 2.72 |
| 2016-05-22 | Blanck (Ronald Ray) | Director | Buy | 3500 | 2.62 |
| 2016-04-30 | Jebsen (Michael B) | Chief Financial Officer | Buy | 430 | 2.72 |
| 2016-02-02 | Mitchum James P | Director | Buy | 13900 | 2.65 |
| 2016-02-01 | Mitchum James P | Director | Buy | 5100 | 2.68 |
| 2016-02-01 | Blanck (Ronald Ray) | Director | Sell | 1800 | 2.69 |
| 2016-01-28 | Jebsen (Michael B) | Chief Financial Officer | Sell | 56 | 2.65 |
| 2015-11-18 | Blanck (Ronald Ray) | Director | Buy | 1900 | 3.20 |
| 2015-11-18 | Blanck (Ronald Ray) | Director | Buy | 4700 | 3.26 |
| 2015-10-30 | Jebsen (Michael B) | Chief Financial Officer | Sell | 49 | 3.19 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| BNY Mellon Investment Management | -- | -- | -33295 | -100.00% | 2019-03-31 |
| Advisor Group, Inc. | 6615 | 0.11% | 6615 | -- | 2019-03-31 |
| Vanguard Group Inc | 12200 | 0.20% | -- | -- | 2019-03-31 |
| JANE STREET GROUP, LLC | 19252 | 0.31% | 19252 | -- | 2019-03-31 |
| Geode Capital Management, LLC | 27658 | 0.45% | -27658 | -50.00% | 2019-03-31 |
| Fidelity Management & Research Company | 33022 | 0.53% | -- | -- | 2019-07-31 |
| Financial Advisory Service Inc | 58576 | 0.95% | -- | -- | 2019-03-31 |
| Renaissance Technologies Corp | 242241 | 3.91% | 77500 | 47.04% | 2019-03-31 |
| BlackRock Inc | 599102 | 9.67% | 598475 | 95450.56% | 2019-03-31 |
| UBS Group AG | 5817 | 0.09% | -2098 | -26.51% | 2019-03-31 |
| Northern Trust Investments Inc | 3306 | 0.05% | 44 | 1.35% | 2019-07-31 |
| BlackRock Asset Management Canada Ltd | 2508 | 0.04% | -2 | -0.08% | 2019-07-31 |
| Sabby Management LLC | -- | -- | -108427 | -100.00% | 2019-03-31 |
| Ladenburg Thalmann FI Services Inc | 18 | -- | -- | -- | 2019-03-31 |
| Morgan Stanley Smith Barney LLC | 50 | -- | -- | -- | 2019-03-31 |
| Morgan Stanley - Brokerage Accounts | 74 | -- | -1 | -1.33% | 2019-03-31 |
| USAA Asset Management Company | 94 | -- | -- | -- | 2019-07-31 |
| Barclays PLC | 100 | -- | -- | -- | 2019-03-31 |
| BlackRock Advisors (UK) Ltd | 100 | -- | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 627 | 0.01% | -- | -- | 2019-07-31 |
| Mellon Investments Corporation | -- | -- | -4782 | -100.00% | 2019-03-31 |
| Karp Capital Management Corporation | 15 | -- | 15 | -- | 2018-12-31 |
| Armistice Capital, LLC | 84590 | 1.37% | 84590 | -- | 2018-12-31 |
| Bank of New York Mellon Corp | 38077 | 0.61% | 38077 | -- | 2018-12-31 |
| Bank of America Corporation | 39 | -- | 33 | 550.00% | 2018-09-30 |
| Dimensional Fund Advisors, Inc. | -- | -- | -14659 | -100.00% | 2018-12-31 |
| Honkamp Krueger Financial Services Inc | 4 | -- | 4 | -- | 2018-09-30 |
| Group One Trading, LP | 8 | -- | -- | -- | 2018-09-30 |
| Deutsche Bank AG | -- | -- | -805 | -100.00% | 2018-09-30 |
| Prime Capital Investment Advisors, LLC | -- | -- | -100 | -100.00% | 2018-09-30 |
| Vanguard | -- | -- | -430 | -100.00% | 2019-01-31 |
| Dimensional Fund Advisors LP | 12650 | 0.42% | -- | -- | 2019-01-31 |
| Wells Fargo & Co | -- | -- | -1 | -100.00% | 2018-06-30 |
| BNY Mellon Asset Management North America Corporation | 401 | 0.03% | 350 | 686.27% | 2018-11-30 |
| UBS Securities LLC | 2984 | 0.20% | 1006 | 50.86% | 2018-06-30 |
| Hanson Mcclain Inc | 1 | -- | 1 | -- | 2018-03-31 |
| Wells Fargo Advisors, LLC | 1 | -- | 1 | -- | 2018-03-31 |
| Virtu Financial LLC | 12576 | 0.86% | 12576 | -- | 2018-03-31 |
| Merrill Lynch & Co Inc | 6 | -- | 1 | 20.00% | 2018-06-30 |
| Mellon Capital Management Corporation | 1646 | 0.11% | 350 | 27.01% | 2018-06-30 |
| Hudock Moyer Wealth Resources, LLC | 1 | -- | 1 | -- | 2018-03-31 |
| Columbia Management Company | 1 | -- | 1 | -- | 2018-03-31 |
| Royal Bank Of Canada | 1 | -- | 1 | -- | 2018-03-31 |
| Vanguard Group Inc. | 188 | 0.01% | -- | -- | 2018-04-30 |
| RA Capital Management, LLC | 2389700 | 8.50% | -- | -- | 2016-12-31 |
| Baker Bros Advisors LP | 348374 | 1.24% | 215400 | 161.99% | 2017-09-30 |
| Millennium Management LLC | 161600 | 0.57% | -342 | -0.21% | 2017-09-30 |
| Citadel Advisors Llc | 82179 | 0.29% | 41651 | 102.77% | 2017-09-30 |
| Northern Trust Investments N A | 51187 | 0.18% | -- | -- | 2017-09-30 |
| Verition Fund Managegment, LLC | 32140 | 0.12% | -- | -- | 2017-09-30 |
| TWO SIGMA SECURITIES, LLC | 21500 | 0.08% | 21500 | -- | 2017-09-30 |
| Cutter & CO Brokerage, Inc. | 15000 | 0.05% | 15000 | -- | 2017-12-31 |
| Cardinal Capital Management | 10000 | 0.04% | -- | -- | 2017-12-31 |
| Morgan Stanley & Co Inc | 2680 | 0.01% | 2470 | 1176.19% | 2017-09-30 |
| BlackRock Advisors LLC | 1873 | 0.01% | -- | -- | 2017-12-31 |
| BlackRock Japan Co Ltd | 1100 | -- | 1100 | -- | 2016-09-20 |
| WFG Advisors, LP | 15000 | 0.05% | -- | -- | 2017-06-30 |
| KCG AMERICAS LLC | 85353 | 0.30% | 85353 | -- | 2017-06-30 |
| Tower Research Capital LLC | 13046 | 0.05% | 13046 | -- | 2017-06-30 |
| Broadfin Capital, LLC | 1968631 | 7.00% | -- | -- | 2016-09-30 |
| Great Point Partners LLC | 1108593 | 3.94% | -- | -- | 2016-09-30 |
| Opaleye Management Inc | 390000 | 1.39% | -75000 | -16.13% | 2016-09-30 |
| EverPoint Asset Management, LLC | 345000 | 1.23% | 195000 | 130.00% | 2016-09-30 |
| Commerzbank AG | 200000 | 0.71% | -100000 | -33.33% | 2016-09-30 |
| Bourgeon Capital Management LLC | 94000 | 0.33% | 28500 | 43.51% | 2016-09-30 |
| Oppenheim Asset Mgmt Services S.¨¤ r.l. | 92900 | 0.33% | -- | -- | 2016-09-30 |
| Apo Asset Management GmbH | 103966 | 0.37% | -- | -- | 2016-12-31 |
| Medical Strategy GmbH | 96200 | 0.35% | -- | -- | 2016-12-31 |
| Nationwide Fund Advisors | 70000 | 0.25% | 10000 | 16.67% | 2016-09-30 |
| John P. Kelley | 1613121 | 8.00% | 5952416 | 0.10% | 1999-11-30 |
| Doug Randall | 1613121 | 8.00% | 5952416 | 0.10% | 1999-11-30 |
| Sabby Healthcare Master Fund, Ltd. | 2354567 | 8.00% | 8688352 | 0.10% | 1999-11-30 |
| Gregory Pepin | 2364956 | 8.00% | 8726688 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| DFA US Small Cap Portfolio | -- | -- | -6712 | -100.00% | 2018-12-31 |
| Vanguard Extended Market Index Fund | 12200 | 0.20% | -- | -- | 2019-06-30 |
| NT Ext Equity Market Index Fund - L | 1240 | 0.02% | -- | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 1057 | 0.02% | -- | -- | 2019-06-30 |
| NT Ext Equity Mkt Fd - DC - NL | 756 | 0.01% | 55 | 7.85% | 2019-06-30 |
| iShares Core S&P Total US Stock Mkt ETF | 627 | 0.01% | -- | -- | 2019-07-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | 627 | 0.01% | -- | -- | 2019-05-30 |
| iShares Core Growth ETF Portfolio | 627 | 0.01% | -- | -- | 2019-05-30 |
| iShares Core Balanced ETF Portfolio | 627 | 0.01% | -- | -- | 2019-05-30 |
| iShares Core S&P US Total Market ETF | 627 | 0.01% | -- | -- | 2019-05-30 |
| NT US Market Cap Index Fund - Lending | 253 | -- | -- | -- | 2019-06-30 |
| USAA Extended Market Index Fund | 94 | -- | -- | -- | 2019-06-30 |
| Fidelity | 51 | -- | -- | -- | 2019-06-30 |
| iShares Core S&P US Total Mkt ETF CADH | -- | -- | -2 | -100.00% | 2019-05-09 |
| DFA US Targeted Value Portfolio | -- | -- | -5938 | -100.00% | 2018-12-31 |
| BNYM Mellon SL Mkt Completion Fd | -- | -- | -371 | -100.00% | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | -- | -- | -1265 | -100.00% | 2019-06-30 |
| Vanguard US Equity Index Fund | -- | -- | -188 | -100.00% | 2018-12-31 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 756 | 0.01% | 55 | 7.85% | 2019-06-30 |
| NT US Market Cap Index Fund - NL | -- | -- | -11 | -100.00% | 2018-12-31 |
| BNYM Mellon NSL Market Completion Fund | 1265 | 0.02% | 1215 | 2430.00% | 2019-03-31 |
| BNYM Mellon SL Market Completion Fund | 371 | 0.01% | -894 | -70.67% | 2019-03-31 |
| The Vanguard Total Stock Market Index | -- | -- | -430 | -100.00% | 2018-06-30 |
| BNY Mellon Market Completion Fund | 50 | -- | -351 | -87.53% | 2018-12-31 |
| Master Extended Market Index Series | -- | -- | -94 | -100.00% | 2018-02-28 |
| Vanguard Balanced Index Fund | 12702 | 0.87% | -18298 | -59.03% | 2017-09-30 |
| Vanguard Total Stock Market Index Fund | 647032 | 44.15% | -- | -- | 2017-07-31 |
| Vanguard Extended Market Idx Inv | 12200 | 0.84% | -- | -- | 2018-07-31 |
| DFA US Small Cap I | 6712 | 0.46% | -- | -- | 2018-07-31 |
| BNY Mellon EB DL Mkt Completion | 1245 | 0.09% | -- | -- | 2018-06-30 |
| DFA US Targeted Value I | 5938 | 0.41% | -- | -- | 2018-07-31 |
| iShares Core S&P Total US Stock Mkt | 627 | 0.05% | -- | -- | 2018-09-12 |
| BNY Mellon Market Completion Fund UC1 | 401 | 0.03% | 350 | 686.27% | 2018-03-31 |
| USAA Extended Market Index | 94 | 0.01% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 69 | -- | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 670313 | 2.38% | -91455 | -12.01% | 2016-12-31 |
| Nationwide Bailard Tech&Sci M | 70000 | 0.25% | -- | -- | 2016-12-31 |
| Vanguard Balanced Index Inv | 31000 | 0.11% | -- | -- | 2016-12-31 |
| iShares Micro-Cap | 56114 | 0.30% | -- | -- | 2017-02-07 |
| AXA/Lord Abbett Micro Cap K | 4318 | 0.02% | -- | -- | 2016-11-30 |
| AZL | 2907 | 0.01% | -- | -- | 2016-12-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 74064 | 0.30% | -- | -- | 2015-09-30 |
| APO Medical Opportunities | 50100 | 0.20% | -- | -- | 2015-10-31 |
| Finen Inversiones SICAV | 39045 | 0.10% | -50 | -0.10% | 2015-06-30 |
| Mellon Capital EB DL Mkt Completion Fund | 31609 | 0.10% | -- | -- | 2015-09-30 |
| Nationwide Bailard Tech&Sci Fund | 25000 | 0.10% | -- | -- | 2015-10-31 |
| apo Medical Opportunities Institutionell | 15000 | -- | -- | -- | 2015-10-31 |
| PHARMA/wHEALTH | 11700 | -- | -- | -- | 2015-09-30 |
| RIM Global CC Bioscience | 5886 | -- | -- | -- | 2015-09-30 |
| AZL® DFA US Small Cap Fund | 5663 | -- | -- | -- | 2015-09-30 |
| Fidelity® NASDAQ Composite Index® Fund | 4974 | -- | -- | -- | 2015-09-30 |
| FCP OP MEDICAL BioHealthTrends | 81200 | 0.30% | -- | -- | 2015-09-30 |
| Ronald R. Blanck | Ronald R. Blanck is a businessperson who has been at the head of 6 different companies. Presently, he is Chairman of VetFed Resources, Inc., Chairman of Martin, Blanck & Associates, Chairman of Tenax Therapeutics, Inc. and Chairman at Pyng Medical Corp. Ronald R. Blanck is also on the board of Ology Bioservices, Inc. and Chairman at Educational Commission for Foreign Medical Graduates, Inc. and Chairman-Regents Board at Uniformed Services University of the Health Sciences. In the past he was Chief-Department of Medicine at Brooke Army Medical Center, Principal at The United States Army (District of Columbia) and President of the University of North Texas Health Science Center. He received an undergraduate degree from Philadelphia College of Osteopathic Medicine. |
|---|---|
| Gerald T. Proehl | Gerald T. Proehl founded Salix Pharmaceuticals Ltd., Santarus, Inc. and Dermata Therapeutics LLC. Presently, Mr. Proehl is President, Chief Executive Officer & Director at Dermata Therapeutics LLC and President of Covella Pharmaceuticals, Inc. Mr. Proehl is also on the board of 6 other companies. He previously held the position of President, Chief Executive Officer & Director at Santarus, Inc., Executive Vice President-Global Marketing at Hoechst Marion Roussel, Inc. and Vice President-Global Marketing at HMR Pharma, Inc. Gerald T. Proehl received a graduate degree from Wake Forest University, an MBA from Rockhurst University and an undergraduate degree from State University of New York College at Cortland. |
| Chris A. Rallis | Chris A. Rallis is on the board of Tenax Therapeutics, Inc., Fennec Pharmaceuticals, Inc., Aeolus Pharmaceuticals, Inc. and Salisbury School, Inc. In his past career Mr. Rallis was President & Chief Executive Officer at ImmunoBiosciences, Inc., President, Chief Operating Officer & Director at Triangle Pharmaceuticals, Inc. and VP-Strategic Planning & Business Development at Burroughs Wellcome. He received a graduate degree from Duke University and an undergraduate degree from Harvard College. |
| Anthony A. DiTonno | Anthony A. DiTonno holds the position of Chairman of Avantis Medical Systems, Inc. and Chief Executive Officer & Director at Tenax Therapeutics, Inc. In his past career Mr. DiTonno held the position of President, Chief Executive Officer & Director at NeurogesX, Inc., President & Chief Executive Officer at LifeSleep Systems, Inc., Principal at Rorer Group, Inc., Principal at Wyeth Laboratories, Inc., Executive Vice President-Sales & Marketing at Enteric Medical Technologies, Inc. and Vice President & General Manager at Oclassen Pharmaceuticals, Inc. Mr. DiTonno received an MBA from Drexel University and an undergraduate degree from St. Joseph's University. |
| James P. Mitchum | James P. Mitchum is a businessperson who has been at the head of 6 different companies and is Chief Executive Officer at Regalorx. He is also on the board of Tenax Therapeutics, Inc. and Medpace Research, Inc. In the past Mr. Mitchum held the position of Chief Executive Officer for Aventis Pharma UK, President & Chief Executive Officer for Sanofi-Aventis Japan, President & Chief Operating Officer for Medi-Flex Ltd., President & Chief Executive Officer of Enturia, Inc., President-Americas Region at EUSA Pharma, Inc., Controller for HMR Pharma, Inc., Controller of Hoechst Marion Roussel, Inc. and Chief Executive Officer & Director at Heart to Heart International, Inc. He received an MBA from the University of Tennessee and an undergraduate degree from Milligan College. |
| Michael B. Jebsen | Michael B. Jebsen occupies the position of President, CFO & Principal Accounting Officer at Tenax Therapeutics, Inc. In his past career Mr. Jebsen occupied the position of Auditor of Grant Thornton LLP, Auditor at Grant Thornton LLP and Chief Ethics Officer & Senior Internal Auditor at Research Triangle Institute. He received a graduate degree from East Carolina University. |
| Gregory Pepin | Gregory Pepin founded Vatea Fund, EOS Investment Ltd. and Independent Wealth Management SA. Currently, he occupies the position of Managing Director at Vatea Fund and Chief Executive Officer for Danish Silver A. Mr. Pepin is also on the board of Tenax Therapeutics, Inc. and Theravectys SAS and Fund Manager at Hades Investment Ltd. and Executive Manager at Deltec Bank & Trust Ltd. Gregory Pepin previously occupied the position of Senior Vice President of Melixia SA, Managing Director at Cedrus Capital LLP and Managing Director at FGP Capital France. Mr. Pepin received an undergraduate degree from the University of Lausanne. |
| Nancy J. Hecox | Presently, Nancy J. Hecox holds the position of Secretary, EVP-Legal Affairs & General Counsel at Tenax Therapeutics, Inc. She is also Member of The North Carolina State Bar. She received an MBA from East Carolina University, an undergraduate degree from The State University of New York and a graduate degree from North Carolina Central University. |
| Doug Randall | Founder of Phyxius Pharma, Inc., Doug Randall presently is Executive VP-Commercial & Business Operations at Tenax Therapeutics, Inc. In the past he was Vice President-Commercial Operations at The Medicines Co., Chief Commercial Officer at Phyxius Pharma, Inc., Vice President-US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals and Vice President-Sales at Aventis Pharmaceuticals, Inc. Doug Randall received an undergraduate degree from the University of Rhode Island. |
| Douglas Hay | Douglas Hay founded Phyxius Pharma, Inc. He is Executive Vice President-Regulatory Affairs at Tenax Therapeutics, Inc. He previously occupied the position of Vice President-Global Regulatory Sciences at Bristol-Myers Squibb Co. and Vice President-Regulatory Affairs at Phyxius Pharma, Inc. Dr. Hay received an undergraduate degree from the University of California, Riverside, a graduate degree from The California State University and a doctorate from Northern Arizona University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论